Continuum Advisory’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
Other funds holding MCRB
FP
LPC
Continuum Advisory's MCRB Position: Q2 2026 in Review
Continuum Advisory opened a new position in Seres Therapeutics (MCRB) in Q2 2026: 47 shares worth $371. The stake represents ﹤0.01% of the portfolio and ranks #1921 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in MCRB as recently as Q1 2025.
Continuum Advisory first reported a position in MCRB in Q1 2024 and has held it in 6 quarters since. The position peaked at $984 in Q1 2024. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.
- Continuum Advisory held 47 shares of Seres Therapeutics worth $371 as of Q2 2026.
- Seres Therapeutics was a new Continuum Advisory position in Q2 2026.
- Seres Therapeutics made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1921 holding.
- Continuum Advisory first reported a position in Seres Therapeutics in Q1 2024 and has held it in 6 quarters since.
- Continuum Advisory's Seres Therapeutics position peaked at $984 in Q1 2024.
- 35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.
Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.